IL6 and endothelial dysfunction: Proinflammatory mediators including TNF-α and IL-6, in addition to ROS, are known to increase the risk of endothelial dysfunction by inhibiting the bioactivity of NO and eNOS and by upregulating the expression of many atherosclerotic factors via the NF-κB pathway.